Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma. Academic Article uri icon

Overview

abstract

  • In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C i.v. every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continuous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxicity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.

authors

  • Reichman, Bonnie S
  • Markman, Maurie
  • Hakes, Thomas
  • Rubin, Stephen
  • Jones, Walter
  • Curtin, John
  • Barakat, Richard
  • Almadrones, Lois
  • Lewis, J L
  • Hoskins, William

publication date

  • July 1, 1993

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Ovarian Neoplasms
  • Platinum
  • Salvage Therapy

Identity

Scopus Document Identifier

  • 0027218276

Digital Object Identifier (DOI)

  • 10.1006/gyno.1993.1159

PubMed ID

  • 8349161

Additional Document Info

volume

  • 50

issue

  • 1